380221-69-2Relevant academic research and scientific papers
SAR of a series of inhaled A2A agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data
Mantell, Simon J.,Stephenson, Peter T.,Monaghan, Sandra M.,Maw, Graham N.,Trevethick, Michael A.,Yeadon, Michael,Walker, Don K.,Selby, Matthew D.,Batchelor, David V.,Rozze, Stuart,Chavaroche, Helene,Lemaitre, Arnaud,Wright, Karen N.,Whitlock, Lynsey,Stuart, Emilio F.,Wright, Patricia A.,Macintyre, Fiona
scheme or table, p. 4471 - 4475 (2010/04/05)
COPD is a major cause of mortality in the western world. A2A agonists are postulated to reduce the lung inflammation that causes COPD. The cardiovascular effects of A2A agonists dictate that a compound needs to be delivered by inhala
